Scientists are exploring the role of tau tangles in Alzheimer’s, and whether addressing these misfolded proteins could treat the disease. Here’s what you need to know.
Great Lakes Clinical Trials is recruiting individuals for the GREEN MEMORY trial. The trial is studying Oligomannate, a drug made from seaweed that has been successfully used for the treatment of Alzheimer’s Disease in China since 2019.
Great Lake’s Empathy Study conducted at their Gurnee site met endpoint goals of the study with an emphasis on an overall 78% reduction of hospitalization and/or ER visits related to COVID-19, or death across ensovibep arms compared to placebo.
Great Lakes Clinical Trials announced that their first participant has been dosed in the Phase 2 randomized, double-blind study of single dose psilocybin vs placebo. The purpose of this research is to study the medical and safety effects of a single dose of psilocybin compared to a placebo in participants with MDD.
On November 8th - Chicago Alzheimer's Awareness Day - Great Lakes Clinical Trials and the Global Alzheimer's Platform Foundation are hosting a major research recruitment event for people in the community who are interested in learning more about memory concerns and Alzheimer's disease.
